Rutten A J, Mather L E, Nancarrow C, Sloan P A, McLean C F
Department of Anaesthesia and Intensive Care, Flinders Medical Centre, Flinders University of South Australia, Bedford Park.
Anesth Analg. 1990 Jun;70(6):577-82. doi: 10.1213/00000539-199006000-00001.
The purpose of this study was to determine the cardiovascular effects and the total body and regional clearances of ropivacaine during its continuous intravenous infusion to subtoxic levels in five conscious unrestrained sheep that had been previously prepared with appropriate intravascular cannulas. Ropivacaine HCl.H2O, 1 mg/min, produced constant arterial blood concentrations which ranged from 0.70 to 1.84 mg/L. This caused no appreciable cardiovascular effects. The mean total body clearance (+/- SD) of ropivacaine was 1.00 +/- 0.27 L/min. There was significant clearance of ropivacaine by the liver (0.85 +/- 0.32 L/min), gut (0.09 +/- 0.07 L/min), and kidneys (0.04 +/- 0.03 L/min). There was no significant clearance of ropivacaine by the lungs, brain, heart, or hindquarters. It was concluded that the liver accounts for the majority of ropivacaine clearance.
本研究的目的是确定在五只预先植入合适血管插管的清醒无拘束绵羊中,将罗哌卡因持续静脉输注至亚中毒水平时的心血管效应以及全身和局部清除率。盐酸罗哌卡因·H₂O以1mg/分钟的速度输注,可产生0.70至1.84mg/L的恒定动脉血浓度。这未引起明显的心血管效应。罗哌卡因的平均全身清除率(±标准差)为1.00±0.27L/分钟。肝脏(0.85±0.32L/分钟)、肠道(0.09±0.07L/分钟)和肾脏(0.04±0.03L/分钟)对罗哌卡因有显著清除作用。肺、脑、心脏或后肢对罗哌卡因无显著清除作用。结论是肝脏是罗哌卡因清除的主要部位。